A Novel Doxorubicin Prodrug with Controllable Photolysis Activation for Cancer Chemotherapy
- Author
- IBSEN, Stuart1 ; ZAHAVY, Eran2 ; WRASDILO, Wolf3 ; BERNS, Michael4 ; CHAN, Michael3 ; ESENER, Sadik5
[1] Department of Bioengineering, Moores Cancer Center University of California San Diego 3855 Health Sciences Dr. # 0815, La Jolla, California 92093-0815, United States
[2] Department of Physical Chemistry Israel Institute for Biological Research PO. Box I9, Ness-Ziona 74100, Israel
[3] Moores Cancer Center, University of California at San Diego, La Jolla, California 92093, United States
[4] Department of Bioengineering, University of California at San Diego, La Jolla. California 92093, United States
[5] Department of Nanoengineering University of California at San Diego, La Jolla, California 92093, United States - Source
Pharmaceutical research. 2010, Vol 27, Num 9, pp 1848-1860, 13 p ; ref : 33 ref
- CODEN
- PHREEB
- ISSN
- 0724-8741
- Scientific domain
- Pharmacology drugs
- Publisher
- Springer, New York, NY
- Publication country
- United States
- Document type
- Article
- Language
- English
- Author keyword
- doxorubicin photoactivatable photocleavable prodrug toxicity
- Keyword (fr)
- Activation Antibiotique Anticancéreux Chimiothérapie Doxorubicine Promédicament Technologie pharmaceutique Toxicité Tumeur maligne Anthracyclines Cancer DNA topoisomerase (ATP-hydrolysing) Enzyme Inhibiteur de la topoisomérase II Inhibiteur enzyme Isomerases Traitement
- Keyword (en)
- Activation Antibiotic Antineoplastic agent Chemotherapy Doxorubicin Prodrug Pharmaceutical technology Toxicity Malignant tumor Anthracyclins Cancer DNA topoisomerase (ATP-hydrolysing) Enzyme Topoisomerase II inhibitor Enzyme inhibitor Isomerases Treatment
- Keyword (es)
- Activación Antibiótico Anticanceroso Quimioterapia Doxorubicina Promedicamento Tecnología farmacéutica Toxicidad Tumor maligno Antraciclinas Cáncer DNA topoisomerase (ATP-hydrolysing) Enzima Inhibidor topoisomerase II Inhibidor enzima Isomerases Tratamiento
- Classification
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B02 Pharmacology. Drug treatments / 002B02A General pharmacology / 002B02A03 Pharmaceutical technology. Pharmaceutical industry
- Discipline
- General pharmacology
- Origin
- Inist-CNRS
- Database
- PASCAL
- INIST identifier
- 23280516
Sauf mention contraire ci-dessus, le contenu de cette notice bibliographique peut être utilisé dans le cadre d’une licence CC BY 4.0 Inist-CNRS / Unless otherwise stated above, the content of this bibliographic record may be used under a CC BY 4.0 licence by Inist-CNRS / A menos que se haya señalado antes, el contenido de este registro bibliográfico puede ser utilizado al amparo de una licencia CC BY 4.0 Inist-CNRS
Access to the document
Install on your browser
DOI
10.1007/s11095-010-0183-x 
https://dx.doi.org/10.1007/s11095-010-0183-x
"O:13:\"PanistOpenUrl\":36:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000idc\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:25:\"10.1007\/s11095-010-0183-x\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:91:\"A Novel Doxorubicin Prodrug with Controllable Photolysis Activation for Cancer Chemotherapy\";s:9:\"\u0000*\u0000jtitle\";s:23:\"Pharmaceutical research\";s:9:\"\u0000*\u0000stitle\";s:10:\"Pharm. res\";s:7:\"\u0000*\u0000date\";s:4:\"2010\";s:9:\"\u0000*\u0000volume\";s:2:\"27\";s:8:\"\u0000*\u0000issue\";s:1:\"9\";s:8:\"\u0000*\u0000spage\";s:4:\"1848\";s:8:\"\u0000*\u0000epage\";s:4:\"1860\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0724-8741\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:5:\"IBSEN\";s:10:\"\u0000*\u0000aufirst\";s:6:\"Stuart\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:5:{i:0;s:12:\"ZAHAVY, Eran\";i:1;s:14:\"WRASDILO, Wolf\";i:2;s:14:\"BERNS, Michael\";i:3;s:13:\"CHAN, Michael\";i:4;s:13:\"ESENER, Sadik\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"PHREEB\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:91:\"A Novel Doxorubicin Prodrug with Controllable Photolysis Activation for Cancer Chemotherapy\";s:8:\"\u0000*\u0000place\";s:12:\"New York, NY\";s:6:\"\u0000*\u0000pub\";s:8:\"Springer\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"13\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Panist access
"O:12:\"IstexOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:25:\"10.1007\/s11095-010-0183-x\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:91:\"A Novel Doxorubicin Prodrug with Controllable Photolysis Activation for Cancer Chemotherapy\";s:9:\"\u0000*\u0000jtitle\";s:23:\"Pharmaceutical research\";s:9:\"\u0000*\u0000stitle\";s:10:\"Pharm. res\";s:7:\"\u0000*\u0000date\";s:4:\"2010\";s:9:\"\u0000*\u0000volume\";s:2:\"27\";s:8:\"\u0000*\u0000issue\";s:1:\"9\";s:8:\"\u0000*\u0000spage\";s:4:\"1848\";s:8:\"\u0000*\u0000epage\";s:4:\"1860\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0724-8741\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:5:\"IBSEN\";s:10:\"\u0000*\u0000aufirst\";s:6:\"Stuart\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:5:{i:0;s:12:\"ZAHAVY, Eran\";i:1;s:14:\"WRASDILO, Wolf\";i:2;s:14:\"BERNS, Michael\";i:3;s:13:\"CHAN, Michael\";i:4;s:13:\"ESENER, Sadik\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"PHREEB\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:91:\"A Novel Doxorubicin Prodrug with Controllable Photolysis Activation for Cancer Chemotherapy\";s:8:\"\u0000*\u0000place\";s:12:\"New York, NY\";s:6:\"\u0000*\u0000pub\";s:8:\"Springer\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"13\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Istex access
"O:16:\"UnpaywallOpenUrl\":35:{s:8:\"\u0000*\u0000email\";s:27:\"assistance-portail@inist.fr\";s:6:\"\u0000*\u0000fmt\";N;s:6:\"\u0000*\u0000doi\";s:25:\"10.1007\/s11095-010-0183-x\";s:6:\"\u0000*\u0000pii\";N;s:7:\"\u0000*\u0000pmid\";N;s:9:\"\u0000*\u0000atitle\";N;s:9:\"\u0000*\u0000jtitle\";N;s:9:\"\u0000*\u0000stitle\";N;s:7:\"\u0000*\u0000date\";N;s:9:\"\u0000*\u0000volume\";N;s:8:\"\u0000*\u0000issue\";N;s:8:\"\u0000*\u0000spage\";N;s:8:\"\u0000*\u0000epage\";N;s:8:\"\u0000*\u0000pages\";N;s:7:\"\u0000*\u0000issn\";N;s:8:\"\u0000*\u0000eissn\";N;s:9:\"\u0000*\u0000aulast\";N;s:10:\"\u0000*\u0000aufirst\";N;s:9:\"\u0000*\u0000auinit\";N;s:10:\"\u0000*\u0000auinitm\";N;s:5:\"\u0000*\u0000au\";N;s:9:\"\u0000*\u0000aucorp\";N;s:7:\"\u0000*\u0000isbn\";N;s:8:\"\u0000*\u0000coden\";N;s:8:\"\u0000*\u0000genre\";N;s:7:\"\u0000*\u0000part\";N;s:9:\"\u0000*\u0000btitle\";N;s:8:\"\u0000*\u0000title\";N;s:8:\"\u0000*\u0000place\";N;s:6:\"\u0000*\u0000pub\";N;s:10:\"\u0000*\u0000edition\";N;s:9:\"\u0000*\u0000tpages\";N;s:9:\"\u0000*\u0000series\";N;s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";N;}"
Unpaywall access
"O:16:\"EuropePMCOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:25:\"10.1007\/s11095-010-0183-x\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:91:\"A Novel Doxorubicin Prodrug with Controllable Photolysis Activation for Cancer Chemotherapy\";s:9:\"\u0000*\u0000jtitle\";s:23:\"Pharmaceutical research\";s:9:\"\u0000*\u0000stitle\";s:10:\"Pharm. res\";s:7:\"\u0000*\u0000date\";s:4:\"2010\";s:9:\"\u0000*\u0000volume\";s:2:\"27\";s:8:\"\u0000*\u0000issue\";s:1:\"9\";s:8:\"\u0000*\u0000spage\";s:4:\"1848\";s:8:\"\u0000*\u0000epage\";s:4:\"1860\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0724-8741\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:5:\"IBSEN\";s:10:\"\u0000*\u0000aufirst\";s:6:\"Stuart\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:5:{i:0;s:12:\"ZAHAVY, Eran\";i:1;s:14:\"WRASDILO, Wolf\";i:2;s:14:\"BERNS, Michael\";i:3;s:13:\"CHAN, Michael\";i:4;s:13:\"ESENER, Sadik\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"PHREEB\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:91:\"A Novel Doxorubicin Prodrug with Controllable Photolysis Activation for Cancer Chemotherapy\";s:8:\"\u0000*\u0000place\";s:12:\"New York, NY\";s:6:\"\u0000*\u0000pub\";s:8:\"Springer\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"13\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Europe PubMed Central access
"O:11:\"BaseOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:25:\"10.1007\/s11095-010-0183-x\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:91:\"A Novel Doxorubicin Prodrug with Controllable Photolysis Activation for Cancer Chemotherapy\";s:9:\"\u0000*\u0000jtitle\";s:23:\"Pharmaceutical research\";s:9:\"\u0000*\u0000stitle\";s:10:\"Pharm. res\";s:7:\"\u0000*\u0000date\";s:4:\"2010\";s:9:\"\u0000*\u0000volume\";s:2:\"27\";s:8:\"\u0000*\u0000issue\";s:1:\"9\";s:8:\"\u0000*\u0000spage\";s:4:\"1848\";s:8:\"\u0000*\u0000epage\";s:4:\"1860\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0724-8741\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:5:\"IBSEN\";s:10:\"\u0000*\u0000aufirst\";s:6:\"Stuart\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:5:{i:0;s:12:\"ZAHAVY, Eran\";i:1;s:14:\"WRASDILO, Wolf\";i:2;s:14:\"BERNS, Michael\";i:3;s:13:\"CHAN, Michael\";i:4;s:13:\"ESENER, Sadik\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"PHREEB\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:91:\"A Novel Doxorubicin Prodrug with Controllable Photolysis Activation for Cancer Chemotherapy\";s:8:\"\u0000*\u0000place\";s:12:\"New York, NY\";s:6:\"\u0000*\u0000pub\";s:8:\"Springer\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"13\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Base Search access
"O:12:\"ArXivOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:25:\"10.1007\/s11095-010-0183-x\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:91:\"A Novel Doxorubicin Prodrug with Controllable Photolysis Activation for Cancer Chemotherapy\";s:9:\"\u0000*\u0000jtitle\";s:23:\"Pharmaceutical research\";s:9:\"\u0000*\u0000stitle\";s:10:\"Pharm. res\";s:7:\"\u0000*\u0000date\";s:4:\"2010\";s:9:\"\u0000*\u0000volume\";s:2:\"27\";s:8:\"\u0000*\u0000issue\";s:1:\"9\";s:8:\"\u0000*\u0000spage\";s:4:\"1848\";s:8:\"\u0000*\u0000epage\";s:4:\"1860\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0724-8741\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:5:\"IBSEN\";s:10:\"\u0000*\u0000aufirst\";s:6:\"Stuart\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:5:{i:0;s:12:\"ZAHAVY, Eran\";i:1;s:14:\"WRASDILO, Wolf\";i:2;s:14:\"BERNS, Michael\";i:3;s:13:\"CHAN, Michael\";i:4;s:13:\"ESENER, Sadik\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"PHREEB\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:91:\"A Novel Doxorubicin Prodrug with Controllable Photolysis Activation for Cancer Chemotherapy\";s:8:\"\u0000*\u0000place\";s:12:\"New York, NY\";s:6:\"\u0000*\u0000pub\";s:8:\"Springer\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"13\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
arXiv access
